Yinjia Bio and IsoPlexis Establish Joint Laboratory in Shanghai to Advance Single-Cell Proteomics for Immuno-Oncology Monitoring

YINJIA BIOSCIENCES and U.S. biotechnology company IsoPlexis recently entered into a Strategic Cooperation Framework Agreement. Both parties will collaborate to advance the application of the IsoPlexis Single-Cell Multiplexed Proteomics Analysis Platform for the real-time dynamic monitoring and analysis of treatment efficacy and early toxicity warnings in patients receiving tumor immunotherapy and cellular immunotherapy.

It is reported that IsoPlexis, founded in 2013 and headquartered in Connecticut, USA, is a biotechnology company specializing in the research and development of cellular response analysis platforms.

(Original text abbreviated)